1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Seroquel XR (quetiapine) (extended-release tablets) is an atypical antipsychotic that is indicated as an adjunctive treatment for MDD in the US, 5EU, and Australia. AstraZeneca initially developed the Seroquel immediate release formulation for the treatment of schizophrenia and bipolar disorder, but has not gained regulatory approvals for MDD with Seroquel. With the development of Seroquel XR, AstraZeneca expanded the label of this product for the treatment of MDD as an adjunctive therapy, initially in 2009 in the US and Australia, followed by an approval in 2010 in the 5EU.

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Seroquel XR including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Seroquel XR for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Seroquel XR performance
- Obtain sales forecast for Seroquel XR from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Classification 13
3.3 Symptoms and Subtypes of Major Depressive Disorder 15
3.4 Prognosis 16
3.5 Quality of Life 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
6 Seroquel XR (Quetiapine) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 32
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 35
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed MDD Patients 37
7.4.2 Percent of Drug-Treated Patients 37
7.4.3 General Pricing Assumptions 38
7.4.4 Individual Drug Assumptions 39
7.4.5 Generic Erosion 39
7.5 Physicians and Specialists Included in this Study 40
7.6 About the Authors 42
7.6.1 Analyst 42
7.6.2 Therapy Area Directors 42
7.6.3 Global Head of Healthcare 43
7.7 About GlobalData 44
7.8 Disclaimer 44

1.1 List of Tables

Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 14
Table 2: Subtypes of Major Depressive Disorder 15
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 17
Table 4: Treatment Guidelines for Major Depressive Disorder 19
Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013 21
Table 6: Leading Treatments for MDD, 2013 27
Table 7: Product Profile - Seroquel XR 29
Table 8: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants 30
Table 9: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events 31
Table 10: Seroquel XR SWOT Analysis, 2014 31
Table 11: Global MDD Sales Forecasts ($m) for Seroquel XR, 2013-2023 32
Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 41

1.2 List of Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 13
Figure 2: Disease Management Model for Major Depressive Disorder 23
Figure 3: Major Depressive Disorder Treatment Algorithm 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • October 2016
  • by Global Data

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2025 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood ...

Major Depressive Disorder - Epidemiology Forecast To 2023

Major Depressive Disorder - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Major Depressive Disorder - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Major Depressive Disorder in seven major markets (US, France, Germany, Italy, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.